Context
UK used to lead in psilocybin research but has fallen behind due to lack of attention from Home Office. American, Canadian and Australian patients can access treatment that British cannot.
Question
The UK used to be a world leader in psilocybin research but, despite the calls of the Home Affairs Committee, leading researchers, charities, veterans' organisations and the Royal College of Psychiatrists, we have shamefully fallen behind on breakthrough treatments for conditions such as post-traumatic stress disorder and depression, causing misery to millions of people in our country. Can the Prime Minister explain why this policy remains the responsibility of a Home Office that cannot give it the attention it deserves, and why it is okay that American, Canadian and Australian patients can access treatment that British patients cannot?
Answer from Rishi Sunak
I completely sympathise and understand why people suffering from distressing conditions will want to seek the best possible treatment available, and I thank the hon. Lady for raising the issue. We are committed to ensuring that the UK is a world-leading jurisdiction for pharmaceutical, clinical and other medical research, and we have asked the Advisory Council on the Misuse of Drugs to review barriers to legitimate medical research involving controlled drugs such as psilocybin. Our response to the council's recommendations will be published as soon as possible.
Not addressed: Specific commitment or timeline for prioritising psilocybin research was not provided
How: Under Review
Was this summary accurate? Tell us
How accurate was this summary? (1 = poor, 5 = spot on)